Live Breaking News & Updates on Cogent Research Team|Page 3

Stay updated with breaking news from Cogent research team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at. ....

United States , San Diego , Pankit Vachhani , Andrew Robbins , Christi Waarich , Mastocytosis Adv , Cogent Research Team , Globenewswire Inc , Division Of Hematology , Cogent Biosciences Inc , University Of Alabama At Birmingham , American Society Of Hematology , Bezuclastinib Clinical Development , Annual Meeting , Associate Professor , Chief Executive , Clinical Development , Gastrointestinal Stromal Tumors , Highly Selective , Tyrosine Kinase Inhibitor , Advanced Systemic Mastocytosis , Results From Part , Private Securities Litigation Reform Act , Quarterly Report ,

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating ...

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose ....

San Diego , United States , Andrew Robbins , Mastocytosis Adv , Christi Waarich , Pankit Vachhani , Division Of Hematology , American Society Of Hematology , Cogent Biosciences Inc , Cogent Research Team , Bezuclastinib Clinical Development , University Of Alabama At Birmingham , American Society , Annual Meeting , Associate Professor , Chief Executive , Clinical Development , Gastrointestinal Stromal Tumors , Highly Selective , Tyrosine Kinase Inhibitor , Advanced Systemic Mastocytosis , Results From Part , Cogent Biosciences , Private Securities Litigation Reform Act , Quarterly Report ,

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating ...

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 ....

United States , San Diego , Prithviraj Bose , Christi Waarich , Frank Siebenhaar , Andrew Robbins , Institute Of Allergology , Head University Outpatient Clinic , Cogent Biosciences Inc , University Of Texas Md Anderson Cancer Center , Department Of Leukemia , Cogent Research Team , American Society Of Hematology , American Society , Annual Meeting , Chief Executive , Cogent Biosciences , Private Securities Litigation Reform Act , Quarterly Report ,

Cogent Biosciences Announces Positive Initial Data from

Cogent Biosciences Announces Positive Initial Data from
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Prithviraj Bose , Christi Waarich , Frank Siebenhaar , Andrew Robbins , Institute Of Allergology , Bezuclastinib Clinical Development , American Society Of Hematology , Cogent Biosciences Inc , Cogent Research Team , Head University Outpatient Clinic , Department Of Leukemia , University Of Texas Md Anderson Cancer Center , American Society , Annual Meeting , Chief Executive , Patient Reported Outcomes , Mast Cell Quality Of Life , Mastocytosis Activity Scale , Patient Global Impression , Clinical Development , Gastrointestinal Stromal Tumors , Cogent Biosciences , Private Securities Litigation Reform Act , Quarterly Report ,

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib. ....

San Diego , United States , Frank Siebenhaar , Prithviraj Bose , Christi Waarich , Andrew Robbins , Head University Outpatient Clinic , Institute Of Allergology , University Of Texas Md Anderson Cancer Center , American Society Of Hematology , Globenewswire Inc , Cogent Research Team , Cogent Biosciences Inc , Department Of Leukemia , Bezuclastinib Clinical Development , Annual Meeting , University Outpatient Clinic , Chief Executive , Patient Reported Outcomes , Mast Cell Quality Of Life , Mastocytosis Activity Scale , Patient Global Impression , Clinical Development , Gastrointestinal Stromal Tumors , Private Securities Litigation Reform Act , Quarterly Report ,